China NMPA Inspection - Weihai Huatai Biotechnology Co., Ltd. - July 29, 2024

An unannounced inspection by Chinese regulatory authorities revealed significant deficiencies in the quality management system of a medical device manufacturer. The inspection, announced on July 29, 2024, identified multiple non-conformities with the Good Manufacturing Practice (GMP) for Medical Devices and its Appendix for Sterile Medical Devices. Key violations included inadequate environmental control, equipment validation, sterilizing agent residue verification, and document management within the aseptic testing laboratory. The company's management representative was deemed ineffective in establishing, implementing, and maintaining the quality management system. In quality control, the manufacturer failed to record critical pore size testing data and neglected to conduct comprehensive finished product release inspections, assessing only a limited number of technical requirements without proper change assessments. Furthermore, testing laboratories lacked essential filtration stages in their fresh air systems, and clean bench validation was incomplete, omitting dust particle testing. Management review processes were also found to be deficient, lacking analysis of product quality data and systemic improvements. Consequently, the company's production has been ordered to suspend. The Shandong Provincial Drug Administration will address potential legal violations and has mandated a thorough assessment of product safety risks, including the recall of any hazardous products. Production can only resume after all deficiencies are fully rectified and a successful re-inspection by the provincial drug administration.